Project Grant R01NS148223
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $566,529 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on April 24, 2026, with completion targeted for March 31, 2031. This research initiative, conducted at Northwestern's Chicago facility, investigates age-related deficits in trophic support of...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $178,208 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 1, 2025, through December 31, 2027. The award funds research to elucidate the critical role of the mitochondrial enzyme MDH2 (malate dehydrogenase 2) in energy metabolism...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $1.84 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 15, 2026, with completion scheduled for March 31, 2029. The award funds preclinical research to develop a gene therapy targeting tauopathies—a group of neurodegenerative disorders...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $769,995 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded August 1, 2025, with completion scheduled for July 31, 2029. This award funds research to elucidate the functional genetic basis of KCNB1 encephalopathy, a rare developmental and epileptic...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $457,112 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) for the period January 1, 2026 through December 31, 2030. The research project investigates Death Induced by Survival Elimination (DISE), a cellular death mechanism involving short RNAs (sRNAs) that target genes critical for cell survival. The research focuses on understanding how DISE...
- Federal Project Grant Award Summary Northwestern University received a $438,606 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025 through July 31, 2027. The research project focuses on establishing induced pluripotent stem cell (iPSC)-based models to investigate the mechanistic interaction between neurotrauma and amyotrophic...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $214,329 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on May 6, 2026, with completion scheduled for April 30, 2028. The research will be conducted at Northwestern's Chicago, Illinois facility and investigates infection-driven...
- Federal Grant Award Summary Northwestern University received a $874,094 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 1, 2025 through July 31, 2030. The research project addresses the pathophysiology of KCNQ2-related disorders, specifically investigating how mutations in the KCNQ2 gene impair the assembly and physiology of...
- Federal Project Grant Award Summary Northwestern University received a $1.44 million Project Grant (DP2 mechanism) from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded August 1, 2025, with completion targeted for July 31, 2028. This award supports the development of next-generation RNA precision medicines to treat severe neurodevelopmental diseases, particularly early-onset epilepsy and treatment-resistant seizure...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $148,614 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective February 15, 2026, with completion targeted for January 31, 2029. The award funds research investigating the clinical, anatomic, and pathologic progression of semantic language impairment in the Type C variant of frontotemporal lobar degeneration due to TDP-43 (TDP-C) pathology....
Northwestern University's Sponsored Research Division received a $634,938 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2026, through May 31, 2031. The award supports fundamental and translational research investigating RNA editing dysregulation in Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD), focusing on how adenosine-to-inosine (A-to-I) RNA editing contributes to pathogenic protein aggregation and neurodegeneration. The research deliverables include three primary aims: (1) determining how A-to-I editing influences subcellular RNA location and identifying specific messenger RNAs sequestered within pathogenic nuclear inclusions composed of RNA binding proteins NONO and SFPQ; (2) assessing connections between mitochondrial and endoplasmic reticulum-Golgi trafficking dysfunction in disease pathogenesis; and (3) validating findings in postmortem brain tissue from DLB patients. The research utilizes induced pluripotent stem cell-derived cortical and midbrain neurons to model disease phenotypes at early and late stages, with the objective of advancing understanding of proteostasis failure mechanisms and identifying potential therapeutic targets in neurodegenerative disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $634.9k | 5/11/26 |